Mucoadhesive micelles for delivery of drugs to the lung for the prophylactic treatment of COVID-19

用于向肺部输送药物以预防性治疗 COVID-19 的粘膜粘附胶束

基本信息

批准号：
552991-2020
负责人：
Sheardown, Heather
金额：
$ 3.64万
依托单位：
McMaster University
依托单位国家：
加拿大
项目类别：
Alliance Grants
财政年份：
2020
资助国家：
加拿大
起止时间：
2020-01-01 至 2021-12-31
项目状态：
已结题

来源：
https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=704114
关键词：
Mucoadhesive micelles delivery drugs lung

项目摘要

The soaring death tolls from COVID-19 and the non-sustainability of the current economic situation pose an urgent worldwide need for an innovative solution to protect the public upon the anticipated restart of the economy. This project will focus on the development of a nasal spray formulation for post-exposure prophylaxis against COVID-19 which will help control the number of infections and, in turn, hasten the safe return of the public to normal life as well as being useful for control in the anticipated second wave. This proposal offers an innovative, straightforward and scalable prophylactic approach that can be self-administered by combining anti-viral drugs with proprietary and patented mucoadhesive micelles to provide a prolonged protective effect against infection. We will focus on the formulation of a nasal spray containing either hydroxychloroquine (HCQ) or a novel Angiopoietin-Tie2 inhibitor, which is proprietary to our partner Mannin Research Inc. Each drug will be incorporated into the patented mucoadhesive micelle delivery system from the Sheardown lab. These formulations will act as a prophylactic, either preventing entry of SARS-CoV-2, the virus responsible for COVID-19, into the respiratory tract or minimizing its impact and severity. They will then be developed for clinical use in partnership with Mannin.

Covid-19的死亡人数高涨，当前经济状况的不可持续性构成了全世界的紧急需求，需要创新的解决方案，以保护公众在预期的经济重新启动下。该项目将着重于开发针对Covid-19的暴露后预防的鼻喷涂配方，这将有助于控制感染的数量，进而加快公众对正常生命的安全回报，并在预期的第二波中对控制有用。该提案提供了一种创新，直截了当且可扩展的预防方法，可以通过将抗病毒药物与专有和专利的粘膜粘附性胶束结合起来来自我管理，从而提供了长时间的保护作用，以防止感染。我们将重点介绍含有羟氯喹（HCQ）的鼻喷雾剂或新型的angiopoietin-Tie2抑制剂，该抑制剂是我们合作伙伴Mannin Research Inc.的专有的。每种药物都将纳入专利的粘液粘膜胶合胶束递送系统中。这些配方将充当预防性，要么防止导致COVID-19的病毒SARS-COV-2进入呼吸道，要么最小化其影响和严重程度。然后，将与Mannin合作开发供临床使用。